Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration
| Autor: | Anat Arodi-Golan, Mordechai Shalem, Idit Lavi, Orna Geyer, Yulia Wolfson, Shaul Sar, Nurit Mathalone |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A Intraocular pressure medicine.medical_specialty Time Factors genetic structures Bevacizumab Ocular hypertension Glaucoma Angiogenesis Inhibitors Antibodies Monoclonal Humanized Cellular and Molecular Neuroscience Tonometry Ocular Sex Factors Risk Factors Ophthalmology Age related medicine Prevalence Humans Intravitreal bevacizumab Intraocular Pressure Aged Retrospective Studies Aged 80 and over business.industry Retrospective cohort study Macular degeneration Middle Aged medicine.disease eye diseases Sensory Systems Intravitreal Injections Retreatment Wet Macular Degeneration Female Ocular Hypertension sense organs business medicine.drug |
| Zdroj: | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 250(10) |
| ISSN: | 1435-702X |
| Popis: | The use of intravitreal anti-VEGF agents in general, and of bevacizumab (Avastin) in particular, has become the common first-line treatment of neovascular age-related macular degeneration (AMD). Several reports addressed the possible elevation of intraocular pressure (IOP) following intravitreal injection of anti-VEGF. The aim of this study was to determine the prevalence of sustained IOP elevation following intravitreal bevacizumab injections for neovascular AMD and identify possible risk factors for the development of increased IOP. This retrospective cohort study included 174 consecutive patients (201 eyes) receiving intravitreal bevacizumab (1.25 mg/0.05 ml) as treatment for neovascular AMD. The records of the study patients were reviewed for age, gender, history of glaucoma, phakic status, IOP levels, length of follow-up, total number of injections, intervals between injections, and IOP management in eyes that exhibited IOP elevation. Sustained IOP elevation was defined as IOP ≥22 mmHg and a change from baseline of ≥6 mmHg recorded on at least two consecutive visits and lasting ≥30 days. Risk factors for an IOP increase were identified from the association between the studied variables and IOP elevations. Sustained IOP elevation was found in 22 of 201 eyes (11%). The increased IOP was controlled with topical medications in all eyes. Among the variables studied, only male gender [OR = 3.1, 95% CI (1.1, 8.5) p = 0.029] and length of interval between injections |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink